Blood and marrow transplant - SA Health Approved Cancer Chemotherapy Protocol Register

Mobilisation

Mobilisation
Protocol Administration at chemotherapy unit level Review Date
Mobilisation of peripheral blood stem cells using plerixafor and G-CSF High February 2024
Peripheral blood stem cell (PBSC) mobilisation protocol CYCLOPHOSPHamide High August 2022

Allogeneic

Allogeneic protocols
Protocol Administration at chemotherapy unit level Review date
Allogeneic intermediate intensity conditioning protocol (cord) CYCLOPHOSPHamide fludarabine thiotepa and total body irradiation (TBI) High August 2023
Allogeneic reduced intensity conditioning protocol FluBu2 (fludarabine and busulfan) High February 2023
Allogeneic myeloablative conditioning (Haploidentical) fludarabine and total body irradiation (TBI) High August 2024
Allogeneic myeloablative conditioning protocol FluBu4 (fludarabine and busulfan) High August 2024
Allogeneic myeloablative conditioning protocol CYCLOPHOSPHamide and busulfan (reversed order) High August 2022
Allogeneic myeloablative conditioning protocol CYCLOPHOSPHamide and total body irradiation (TBI) High August 2022
Allogeneic non myeloablative conditioning protocol (Haploidentical) CYCLOPHOSPHamide fludarabine and total body irradiation (TBI) High August 2022
Allogeneic reduced intensity conditioning protocol fludarabine and melphalan
SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution
High February 2027

Autologous

Patient treatment scheduling may differ between sites depending on local procedures

Autologous protocols
Protocol Administration at chemotherapy unit level Review date
Autologous conditioning diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) overview High August 2023
Diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) induction MATRix (methotrexate cytarabine thiotepa and rituximab) - part 1 High August 2023
Diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) induction RICE (rituximab ifosfamide carboplatin and etoposide) - part 2 High August 2023
Autologous conditioning diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA) carmustine and thiotepa - part 3 High August 2023
Autologous conditioning protocol BEAM (carmustine etoposide cytarabine melphalan)
SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution
High August 2022
Autologous conditioning protocol busulfan and melphalan
SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution
High August 2024
Autologous conditioning protocol germ cell tumour TICE treatment overview High August 2022
Autologous conditioning protocol germ cell tumour TICE (cARBOplatin and Etoposide) (part 2) High August 2022
Autologous conditioning protocol germ cell tumour TICE (PACLItaxel and IFOSFamide) (part 1) High August 2022
Autologous conditioning protocol high dose melphalan 140 mg/m2
SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution
High August 2022
Autologous conditioning protocol high dose melphalan 200 mg/m2
SAHCDC approved variation to melphalan expiry time based SA Pharmacy advice - infusion to be completed no later than 90 minutes after reconstitution
High August 2026
Autologous conditioning protocol primary CNS lymphoma carmustine and thiotepa High August 2024
Autologous conditioning relapsed CNS lymphoma overview High August 2024
Relapsed CNS lymphoma induction iFOSFamide liposomal cytarabine methotrexate - part 1 High August 2024
Relapsed CNS lymphoma induction cytarabine liposomal cytarabine thiotepa - part 2(a) High August 2024
Relapsed CNS lymphoma induction cytarabine liposomal cytarabine thiotepa - part 2(b) High August 2024
Autologous conditioning relapsed CNS lymphoma carmustine etoposide thiotepa - part 3 High August 2024

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.